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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYThe application of cell-based therapies in regenerative medicine is gaining recognition. Here, we show that human bonemarrow stromal
cells (BMSCs), also known as bone-marrow-derived mesenchymal cells, can be reprogrammed into renal proximal tubular-like epithelial
cells using cell-free extracts. Streptolysin-O-permeabilized BMSCs exposed to HK2-cell extracts underwent morphological changes—for-
mation of ‘‘domes’’ and tubule-like structures—and acquired epithelial functional properties such as transepithelial-resistance, albumin-
binding, and uptake and specific markers E-cadherin and aquaporin-1. Transmission electronmicroscopy revealed the presence of brush
border microvilli and tight intercellular contacts. RNA sequencing showed tubular epithelial transcript abundance and revealed the up-
regulation of components of the EGFR pathway. Reprogrammed BMSCs integrated into self-forming kidney tissue and formed tubular
structures. Reprogrammed BMSCs infused in immunodeficient mice with cisplatin-induced acute kidney injury engrafted into proximal
tubuli, reduced renal injury and improved function. Thus, reprogrammed BMSCs are a promising cell resource for future cell therapy.INTRODUCTION
Cell-based therapies are emerging as one of themost prom-
ising approaches of regenerative medicine (Riazi et al.,
2009). In the kidney field, the search for a renal-specific
stem cell led to the discovery of progenitor cells that protect
animals from acute kidney injury (AKI) when systemically
infused (Angelotti et al., 2012; Benigni et al., 2010). How-
ever, the cell number is a limiting factor, and their biology
is far from known. Therefore, other non-renal stem cell
sources have been pursued. Derivation of human embry-
onic stem cells (hESCs) (Thomson et al., 1998) has raised
hope because they can give rise to all three germ layers,
but progress toward somatic populations has encountered
major obstacles, including the risk of cancer and rejection,
not to mention the ethical issues involved. The same holds
true for induced pluripotent stem cells (iPSCs) (Takahashi
and Yamanaka, 2006), which are similar to hESCs but
devoid of at least some of the above problems. The genera-
tion of hESC/iPSC-derived mature renal cells (Song et al.,
2012) and, more recently, intermediate mesoderm/meta-
nephric mesenchyme (MM) and ureteric bud (UB) renal
progenitors (Lam et al., 2014; Lin et al., 2010; Mae et al.,
2013; Takasato et al., 2014) has been reported. In principle,Stempatient-specific cells to be used therapeutically could be
obtained through reprogramming approaches in which a
long-standing interest exists because of the possibility
that abundant adult cells can easily be harvested and con-
verted to other cell types (Zhou et al., 2008). In this context,
studies have defined sets of transcription factors that can
directly reprogram somatic cells into another cell type
without passing through the pluripotent state (Ginsberg
et al., 2012; Ieda et al., 2010; Karow et al., 2012; Vierbuchen
et al., 2010). Using a strategy of re-expressing key develop-
mental regulators in vitro/in vivo, adult cell reprogram-
ming occurs, through which induced cells residing in their
native environment might promote their survival and/or
maturation (Ginsberg et al., 2012; Ieda et al., 2010; Karow
et al., 2012; Qian et al., 2012; Vierbuchen et al., 2010;
Zhou et al., 2008).
In parallel with these developments, an intriguing tech-
nology for direct cell reprogramming by exposing revers-
ibly permeabilized somatic cells to cell-free extracts has
emerged. This method has its origins in the early experi-
ments of Briggs and King, followed by Gurdon (Gurdon,
2006), where a somatic cell nucleus was transferred
(SCNT [somatic cell nuclear transfer]) to an enucleated
oocyte, resulting in the activation of the somatic cellCell Reports j Vol. 4 j 685–698 j April 14, 2015 j ª2015 The Authors 685
nucleus. Cell-extract reprogramming was first demon-
strated with extracts of regenerating newt limbs, which
promoted cell-cycle re-entry and downregulation of
myogenic markers in differentiated myotubes (McGann
et al., 2001). Afterward, this approach yielded in-vitro-
reprogrammed somatic cells with the extracts from
T cells, cardiomyocytes, insulinoma cells, pneumocytes,
chromaffin, or embryonic stem cells (Gaustad et al., 2004;
Ha˚kelien et al., 2002, 2004; Landsverk et al., 2002; Qin
et al., 2005; Qu et al., 2013; Rajasingh et al., 2008).
Surprisingly, there is a paucity of attempts at the reverse
reprogramming of adult stem cells toward somatic cells.
Human bone marrow stromal cells (BMSCs), also known
as bone-marrow-derivedmesenchymal stem cells, are adult
stem/progenitor cells with self-renewal capacity and
restricted potential for generating skeletal tissues, includ-
ing osteoblast, chondrocyte, adipocyte, and perivascular
stromal cells (Bianco et al., 2013; Le Blanc and Mougiaka-
kos, 2012). Whether BMSCs can be used therapeutically is
still a matter of debate. Based on their paracrine action
rather than differentiation ability, these cells have been
used with promising results in different diseases (Le Blanc
and Mougiakakos, 2012; Morigi and Benigni, 2013; Rein-
ders et al., 2014; Souidi et al., 2013). No evidence of direct
reprogramming of BMSCs into somatic cells is available yet.
Here, we inquired whether human BMSCs could be
reverse reprogrammed to acquire a renal tubular epithelial
phenotype by using tubular cell extracts. We found that
reprogrammed BMSCs (1) acquired an antigenic profile
and functional properties of proximal tubular-like epithe-
lial cells in vitro, (2) integrated into developing nephrons
ex vivo, and (3) protected mice from AKI.RESULTS
Morphological and Ultrastructural Characteristics
of BMSCs Treated with HK2 Cell Extracts
Human BMSCs were permeabilized with 400 ng/ml strep-
tolysin O (SLO), a concentration that did not affect
cell viability. Permeabilized BMSCs exposed to the extract
of human proximal tubular epithelial (HK2) cells changed
from their usual spindle-shape appearance (Figure 1A) to
cobblestone islands within 13–15 days (Figures 1B–1D).
During the subsequent 2 weeks, these islands expanded
and the formation of ‘‘domes’’ and tubular-like structures
(Figures 1E and 1F) similar to HK2 cells (Figure 1H)
occurred. This morphological transition did not occur
in BMSCs grown in epithelial-specific culture medium,
even after 35 days (Figures 1I and 1J). The observed change
in morphological appearance of BMSCs treated with
epithelial cell extract suggested a phenotypic switch in
the cells.686 Stem Cell Reports j Vol. 4 j 685–698 j April 14, 2015 j ª2015 The AuthoMoreover, transmission electron microscopy (TEM) of
cell-extract-treated BMSCs demonstrated brush border
microvilli and images of tight intercellular contact (Figures
1K–1M), further confirming that cells acquired a proximal
tubular-like epithelial phenotype similar to HK2 cells
(Figures 1N and 1O). BMSCs treated with HK2 cell medium
did not demonstrate any apical specialization or cell-cell
contact, even after 35 days (Figure 1P).
Antigenic Profile of the BMSCs Treated with HK2 Cell
Extracts
To explore the renal identity of BMSCs treatedwithHK2 cell
extracts, we studied candidate proximal tubular epithelial
cell markers using immunofluorescence microscopy and
flow cytometry (fluorescence-activated cell sorting [FACS])
analysis. BMSCs consistently expressed endoglin (ENG;
also known as CD105), characteristic of the mesenchymal
lineage, and were devoid of the epithelial markers E-cad-
herin (CDH1) and aquaporin-1 (AQP1) (Figures S1A–S1D).
After 8 days, BMSCs treated with HK2 cell extracts weakly
expressed CDH1, TJP1 (tight junction protein 1; also
known as zona occludens-1), and AQP1 in combination
with BMSC markers (Figures 2A–2D). Moreover, after
25 days, BMSCs treated with HK2 cell extracts displayed
robust expression of the epithelial markers but substan-
tially reduced expression of ENG (Figures 2E and 2H),
which is consistent with the expression profile of HK2 cells
(Figures S1E–S1H).Notably, BMSCs thatwerenot converted
to cobblestone islands maintained the expression of
mesenchymal markers (Figures 2E and 2H, area defined by
the dotted line). BMSCs grown in HK2 cell medium, used
as control, did not express epithelial markers and retained
the expression of ENG (Figures S1I–S1L).
To quantify the BMSC reprogramming process, FACS
analysis was performed. By day 8, a cell population of
1%–3% of BMSCs treated with HK2 cell extracts expressed
AQP1 and CDH1 (Figure 2I). The highest percentage of
reprogrammed BMSCs expressing these tubular epithelial
markers was observed after 35 days and averaged 15%–
21% (Figure 2I).
To trace the reprogramming process chronologically, we
used an EGFP plasmid containing the promoter region of
CDH1 (Genecopeia; HPRM12692-PF02). Human BMSCs
were transfected at days 5 and 11 from cell-extract expo-
sure, and CDH1/EGFP-positive cells were assessed 24 hr
later (days 6 and 12). At day 6, the EGFP-positive cells
had a BMSC-like shape, while at day 12, CDH1/EGFP-posi-
tive cells acquired an epithelial-like appearance (Figure 2J).
The reprogramming efficiency was 0.01%–0.02%. Un-
treated BMSCs grown in HK2 cell medium did not express
EGFP at any time points tested (Figure 2J). As expected,
several HK2-transfected cells became positive for CDH1/
EGFP, with a transfection efficiency of 30% (Figure 2J).rs
Figure 1. Morphological and Ultrastruc-
tural Changes in Human BMSCs after
HK2 Cell-Extract Treatment
(A) Human BMSC morphology 24 hr after
extract treatment (D1).
(B) Cobblestone morphology of the BMSCs
13 days (D13) after extract treatment.
(C) Epithelial colony 15 days (D15) after
extract treatment.
(D) High magnification of the epithelial
colony showing the cobblestone cell
morphology.
(E and F) Dome formation (E, arrows) and
tubular structures (F) after 25- and 35-day
BMSC extract treatment (D25 and D35),
respectively.
(G) Control HK2 cell morphology on the day
of the extract preparation.
(H) Dome formation (arrows) under over-
confluence culture conditions.
(I and J) BMSCs cultured in HK2 cell culture
media at 24 hr (I, D1) and 35 days (J, D35).
Human BMSCs treated with HK2 cell
extract form microvilli and tight intercel-
lular contacts.
(K and L) Details of adjacent BMSCs treated
with extracts grown on Thermanox for
35 days. Tight intercellular contacts are
formed in BMSCs treated with HK2 cell ex-
tracts at D35 (arrowheads).
(M) Brush border formed in a BMSC treated
with extract after 35 days.
(N–P) TEM images of HK2 cells (N and O)
and BMSCs (P) grown in HK2 cell medium for
35 days (D35). Images are representative of
two independent experiments.
Scale bars represent 200 mm (A), 50 mm
(B and D–J), and 100 mm (C). Images
are representative of three independent
experiments.Collectively, these studies revealed that following expo-
sure with HK2 extracts, a subset of BMSCs acquire mor-
phological, ultrastructural, and antigenic hallmarks of
proximal tubular epithelial cells, suggesting that BMSC re-
programming was achieved using this treatment.
Reprogramming of BMSCs Requires Both Nuclear and
Cytoplasmic Cell Extracts
In search of the component(s) of the cell extract respon-
sible for reprogramming, we systematically analyzed
nuclear and cytoplasmic extracts, extracts depleted of
RNA, and proteins or treated with epigenetic modifiers
such as trichostatin A and 5-aza-cytidine. Ablation of
each of these components did not reproduce the effect ofStemthe whole-cell extract (Figure S2). These results are consis-
tent with previously described data on the requirement of
both nuclear and cytoplasmic cell extracts to achieve
reprogramming (Ha˚kelien et al., 2002).
Generation and Characterization of Clones from
Reprogrammed BMSCs
To better characterize the human BMSCs treated with HK2
cell extracts, we next generated clones using a limiting-
dilution approach. Of the 50 clones derived from one re-
programmed human BMSC experiment, the five that
showed the most epithelial-like morphology were sub-
jected to further analysis using qRT-PCR to examine their
mesenchymal and epithelialmarker profile. The expressionCell Reports j Vol. 4 j 685–698 j April 14, 2015 j ª2015 The Authors 687
Figure 2. Antigenic Profile of Human
BMSCs after HK2 Cell-Extract Treatment
(A–H) Expression of ENG, CDH1, TJP1, and
AQP1 in BMSCs treated with extract at D8
(A–D) and D25 (E–H). (H) High-magnifi-
cation view of the expression of ENG and
AQP1 at the edge of the epithelial colony
presented in (E). Scale bar, 50 mm. Repre-
sentative images of three independent
experiments.
(I) Representative FACS analysis of BMSCs
treated with HK2 cell extract at different
time points (D8, D25, and D35), and of
untreated BMSCs and HK2 cells. Values
are % of fluorescent cells (mean ± SD, n = 3
independent experiments).
(J) Representative images of CDH1/EGFP-
positive cells 24 hr after transfection (days
6 and 12). Untreated BMSCs and HK2 cells
are also shown. Scale bars represent 50 mm
(BMSCs + extract [D6, D12] and BMSCs) and
100 mm (HK2). Transfection was performed
in two independent reprogramming experi-
ments (n = 2 for each time point).
See also Figure S1.of ENG, AQP1, and gamma glutamyl transferase 1 (GGT1)
in these five clones is depicted in Figure 3A. The difference
in the expression of these markers reflects heterogeneity in
reprogramming efficiency. Cells from clone 17 (CL17) were
the most similar to HK2 cells and maintained a stable
phenotype and morphology throughout passages. Expres-
sion of AQP1 and GGT1 mRNA has been also evaluated in
primary proximal tubular epithelial cells (PTECs; Fig-
ure S3A). Consistent with the mRNA data, immunocyto-
chemistry revealed that CL17 cells expressed TJP1, AQP1,
and GGT1 proteins (Figure 3B). Scanning electron micro-
scopy (SEM) revealed the presence of microvilli in CL17
similar to HK2 cells (Figure 3C). As expected, BMSCs did
not show any microvilli (Figure 3C). Moreover, CL17 ex-688 Stem Cell Reports j Vol. 4 j 685–698 j April 14, 2015 j ª2015 The Authohibited a duplication time comparable to that of HK2 cells
(CL17: 20.4 ± 1.9 versus HK2: 18.9 ± 1.9 hr) and signifi-
cantly shorter than BMSCs (55.2 ± 4.2 hr, Figure 3D). Alto-
gether, these data indicated that the CL17, generated by
BMSCs treated with the HK2 cell extracts, acquired the
renal tubular epithelial phenotype.
Global Transcriptome Analysis in CL17, HK2,
and BMSCs
To evaluate the global effect of BMSC reprogramming
with cell extracts, we performed poly(A)+ mRNA deep
sequencing in BMSCs and CL17 and HK2 cells (two biolog-
ical replicates each). The homogeneity of the replicates of
each cell type was confirmed by the high intra-grouprs
Figure 3. Characterization of Clones
Generated by Human BMSCs after HK2
Cell-Extract Treatment
(A) Relative expression of ENG, AQP1, and
GGT1 mRNA by qRT-PCR in five selected
clones and in HK2 cells compared to BMSCs.
BMSC mRNA expression was used as the
reference sample. Analyses were performed
in triplicate. See also Figure S3A.
(B) Expression of TJP1, AQP1, and GGT1
proteins in clone 17 (CL17) and in HK2 cells.
Scale bars, 50 mm.
(C) SEM analysis showed no microvilli in
BMSCs. Instead, CL17 cells displayed
microvilli similar to the HK2 cells. Repre-
sentative images of three independent ex-
periments.
(D) Duplication time (hours) in BMSCs, CL17
and HK2 cells (n = 5). Data are expressed as
mean ± SD. *p < 0.01 versus BMSCs.
(E–G) RNA sequencing analysis of BMSCs
and CL17 and HK2 cells. (E) Multidimen-
sional scaling plot based on pairwise dis-
tances between global gene transcriptome
profiles of six analyzed samples (two bio-
logical replicates for each cell lineages). (F)
Workflow of transcriptome analysis showing
the differentially expressed genes (DEGs) in
BMSCs, CL17, and HK2 cells. At the inter-
section of the Venn diagrams, up- or
downregulated genes both in CL17 and HK2
cells compared to BMSCs (top) and those
up- or downregulated both in CL17 and
BMSCs compared to HK2 cells (bottom) are
reported. See also Table S3, which contains
the full list of DEGs. The top 20 down-
and upregulated genes and functionally
characterized DEGs for selected pathways
are reported in Tables S1, S2, and S3,
respectively.
(G) Heatmap of the differentially expressed
genes of the tight junction, brush border,
focal adhesion, and EGFR networks. Columns represent biological replicates, and rows represent each gene. Green and red indicate high and
low expression, respectively. The dendrogram of the unsupervised hierarchical clustering of the analyzed samples is shown in the upper
part of the heatmap.
See also Figures S3–S5 and Tables S1, S2, and S3.correlation coefficients (Figure S3B). Inter-group compari-
sons by scatterplots and Pearson coefficient correlations
indicated a higher degree of similarity between reprog-
rammed CL17 cells and renal tubular HK2 cells (r = 0.957)
than between the CL17 and BMSC cells (r = 0.605) (Figures
S3C–S3E). Additionally, unsupervised hierarchical clus-
tering of the six transcriptomes classified CL17 and
HK2 cells together and separated them from BMSCs
(Figure S4A). The same classification was obtained usingStemmultidimensional scaling, which is another unbiased
method for measuring similarity between large datasets
(Figure 3E). We further foundmore differentially expressed
genes (DEGs) betweenCL17 andBMSCs (2,127 upregulated
and 2,355 downregulated in CL17 compared to BMSCs)
than between CL17 and HK2 cells (120 up- and 61 downre-
gulated in CL17 relative to HK2). Remarkably, 85% of the
CL17 up- or downregulated genes were consistently up- or
downregulated inHK2cells compared toBMSCs (Figure3F).Cell Reports j Vol. 4 j 685–698 j April 14, 2015 j ª2015 The Authors 689
Among the geneswith the greatest fold change, therewas
a dramatic reduction in BMSC-related markers (i.e.,MMP2,
TIMP3, and CDH11) and increased expression of proximal
tubular-cell-related markers (F11R, SLCO4A1, and HNF1B)
(see full list in Tables S1 and S2). In addition, functional
pathway analysis revealed in CL17 cells reduced levels of
genes involved in mesenchymal cell-extracellular matrix
interactions and increased levels of genes involved in
proximal tubular cell-extracellular matrix interactions
including laminins, collagens, and integrins (Table S3).
Furthermore, CL17 showed upregulated expression of mol-
ecules involved in the tight junction and brush border
as well as of several constituents involved in apical and ba-
solateral structures of polarized proximal tubular cells (for
the full list, see Table S3). The fold inductions observed
using RNA sequencing were comparable to those obtained
by qRT-PCR, with an R2 correlation coefficient equal to
0.98, validating the approach (Figures S4B and S4C).
Functional network analysis of the upregulated genes
involved in the process of proximal tubular cell
polarization identified epidermal growth factor receptor
(EGFR) as a candidate upstream regulator (Figures 3G and
S5 and Table S3). Indeed, there was increased expression
in CL17 of EGFR and its ligand, TGFA, as well as
downstream targets such as PRKCZ, PPARG, and SGK1,
which control tight junctions, some organic ion trans-
porters, and regulators of apical membrane components
(Panchapakesan et al., 2011). Remarkably, the above
pathways were shared with HK2 cells (Figures 3G and S5
and Table S3).
Collectively, these data show that the reprogrammed
CL17 cells lost mesenchymal markers and assumed an
expression profile similar to renal tubular HK2 cells.
Functional Properties of CL17 Cells
Transepithelial Electrical Resistance
Having observed the formation of nascent intercellular
contacts, we next inquired whether CL17 cells in addition
to morphological and cell-lineage markers had acquired
physiological properties similar to the epithelial pheno-
type. Testing the electrical resistance of BMSC monolayers
showed trivial values of 34 ± 10 Ohm/cm2. In contrast,
monolayers of CL17 cells developed electrical resistance
similar to that observed in HK2 cells (80 ± 10 versus 81 ±
12 Ohm/cm2) (Figure 4A), both statistically significantly
different from the transepithelial resistance (TER) assessed
in BMSCs.
Albumin Binding and Uptake
Typical properties of proximal tubular epithelium are the
binding and uptake of albumin in a receptor-dependent
way (Gekle et al., 1998). Binding of BSA was studied in
CL17, HK2, and BMSCs by exposing cells for 15 min to
BSA and fluorescein isothiocyanate (FITC) alone or in the690 Stem Cell Reports j Vol. 4 j 685–698 j April 14, 2015 j ª2015 The Authopresence of an excess of cold BSA (Figure 4B, left panels)
at 4C, a condition known to prevent endocytotic pro-
cesses and protein internalization (Ishibashi, 2004; Morigi
et al., 2005; Takakura et al., 1995). As shown in Figure 4B
(left panels), the addition of unlabeled albumin displaced
BSA-FITC in CL17 to an extent comparable to HK2 cells,
indicating the presence of specific binding sites for albu-
min in reprogrammed cells similar to the ones present in
tubular epithelial cells (Figure 4B, left panels).
Uptake of albumin was assessed in cells exposed to
BSA-FITC alone or in the presence of an excess of unlabeled
BSA at 37C for 90 min, an experimental condition previ-
ously described as allowing appreciable protein endocy-
tosis (Ishibashi, 2004; Morigi et al., 2005; Takakura et al.,
1995) (Figure 4B, right panels). Albumin uptake was mark-
edly inhibited by an excess of unlabeled protein, suggest-
ing receptor-mediated endocytosis of BSA-FITC in CL17
comparable to that observed in HK2 cells (Figure 4B, right
panel). Control BMSCs did not exhibit any binding or
uptake of BSA-FITC (Figure 4B, bottom panels).
Altogether, these studies revealed that CL17 cells ac-
quired and maintained functional properties of proximal
tubular-like epithelial cells.
CL17 Cells Contribute to Tubular Structures in Renal
Organoids Ex Vivo
To assess the functional integration into kidney tissue,
human cells (CL17, HK2, or BMSCs) were mixed with kid-
ney cells derived from embryonic day 11.5 (E11.5) mice
(Unbekandt and Davies, 2010; Xinaris et al., 2012), and
grown as explants for 5 days. At day 1, CL17 cells integrated
into the condensing metanephric mesenchyme that was
identified by co-expression of neural cell adhesion mole-
cule (NCAM) and PAX2 markers (Figure 5A, insert).
At day 5, chimeric aggregates of human and mouse cells
grew into elongating tubular structures that were sur-
rounded by laminin-positive basement membranes (Fig-
ures 5B and 5C). Remarkably, tubular structures containing
CL17 or HK2 cells were in close vicinity to glomerular-like
structures expressing the early podocyte marker Wilms tu-
mor 1 (WT1) (Figures 5E and 5F). BMSCs neither formed
nor contributed to renal structures, indicating non-neph-
rogenic potential (Figures 5D and 5G).
CL17 Cells Engraft into Proximal Tubuli and Reduce Renal
Damage in AKI Mice
The renoprotective potential of the reprogrammed cells
was investigated in an experimental murine model of
cisplatin-induced AKI (Morigi et al., 2008). After intrave-
nous injection of CL17 cells, 50% were recovered in
the lung, 1% in the spleen, 0.47% in the liver, and
21% in the kidney; no cells were found in the heart (Fig-
ure S6A). Engrafted CL17 cells, stained for two human
markers for mitochondria and centromere protein-A
(CENP-A), in the renal parenchyma of immunodeficientrs
Figure 4. Functional Properties of CL17 Cells In Vitro
(A) Transepithelial resistance (TER) measurement of CL17, HK2, and BMSCs. Three independent experiments were done in duplicate. Data
are expressed as mean ± SD; *p < 0.01 versus BMSCs.
(B) BSA binding and uptake in CL17, HK2, and BMSCs. Cells were exposed to 50 mg/ml BSA-FITC alone or in the presence of excess cold BSA
(5 mg/ml) for 15 min at 4C for binding experiments (left) and for 90 min at 37C for uptake experiments (right). Images are representative
of three experiments. Scale bars, 50 mm.
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Figure 5. Human CL17, HK2, and BMSC
Integration in Renal Organoids
(A) Human CL17, HK2, or BMSCs were mixed
with fully dissociated E11.5 mouse embry-
onic kidneys and grown as explants for
1–5 days. Representative image of CL17-cell
integration (stained with Cell Tracker,
green) into the condensing metanephric
mesenchyme identified by NCAM1 and PAX2
co-staining at day 1 (insert image).
(B and C) At day 5, chimeric aggregates of
human (immunostained with anti human
nuclear antigen, green; arrowhead) and
mouse cells (asterisk) lay within laminin-
positive membranes (white). Cell nuclei
were labeled with DAPI (blue).
(E and F) CL17 cells (E) and HK2 cells (F)
form elongating tubular structures in
the vicinity of WT1-positive glomerular
structures.
(D and G) BMSCs never formed any renal
structure. Images are representative of
three independent experiments.AKI mice, were localized in the tubular compartment at
4 days post-cisplatin injection (Figure 6A) with a frequency
averaging 213 PKH26+ve cells/100,000 renal cells. CL17
cells predominantly localized within proximal tubuli
(80%) and, to a lesser extent (20%), in the peritubular areas
(Figure 6B). As a positive control for human markers, we
used human BMSCs that were mainly found at the peritub-
ular level in tissues of cisplatin-treated mice (Figure S6B).
Negative controls with non-immune immunoglobulin of
the same isotype as the primary antibody are shown in Fig-
ure S6C. Next, we studied the effect of CL17 cell treatment
on renal function impairment and tubular damage. In
cisplatin-treated mice given CL17 cells, renal function
was ameliorated (Figure 6C), although blood urea nitrogen
(BUN) levels were not significantly different from those
observed in untreated animals (22 ± 2 mg/dl) at 4 days.
In parallel, renal damage was significantly improved in
AKI animals infused with CL17 cells as demonstrated by692 Stem Cell Reports j Vol. 4 j 685–698 j April 14, 2015 j ª2015 The Authothe significant reduction of hyaline casts and necrotic tu-
buli (Figures 6D and 6E). Control mice did not show any
signs of tubular damage. Altogether, these data indicate
that the reprogrammed BMSCs directly incorporated into
proximal tubuli and improved renal damage and function
in AKI mice.DISCUSSION
Our results provide evidence that human BMSCs can be
directly reprogrammed into cells that closely resemble
renal proximal tubular epithelial cells using cell extracts.
The reprogramming of BMSCs is demonstrated by the
acquisition of (1) morphological, ultrastructural, and anti-
genic properties; (2) transcriptomic profile; and (3) func-
tional characteristics of proximal tubular-like epithelial
cells. Notably, the directly reprogrammed cells acquirers
Figure 6. CL17 Cells Engrafted in Proximal Tubuli in Mice with Cisplatin-Induced AKI
(A) Incorporation of CL17 cells into kidney tubuli of mice with cisplatin-induced AKI detected by human mitochondrial (h-Mito, upper-left
panel; brown) and CENP-A (upper-right panel and insets; red) staining. Arrow indicates an h-Mito-positive cell in the proximal tubule
connected to the glomerulus. No h-Mito- and CENP-A-positive cells are present in renal tissue of AKI animals with saline (bottom). DAPI
(blue) stains nuclei, and renal structures are labeled with wheat germ agglutinin (WGA, green). Scale bars represent 10 mm for h-Mito
staining and 20 mm for CENP-A staining.
(B) Renal localization of PKH26/positive CL17 cells (red) in AKI mice within proximal tubuli (top) or in peritubular areas (bottom). DAPI
(blue) stains nuclei, and renal structures are labeled with WGA (green). Scale bars, 20 mm.
(C) Blood urea nitrogen (BUN) (mg/dl) levels in AKI mice treated with CL17 cells (n = 6) or saline (n = 5) at 4 days. Data are expressed as
mean ± SD.
(D) Quantification of tubular casts and necrotic tubuli (n/high-power field [HPF]) in kidneys of AKI mice treated with CL17 cells or saline at
4 days. *p < 0.05 versus cisplatin + saline.
(E) Representative histological micrographs of the kidney of the AKI animals treated with CL17 cells (left) or saline (right) at 4 days. Scale
bar, 50 mm.
See also Figure S6.
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epithelial features and gain organ-forming capacity and
have functional properties to the extent that they reduced
renal damage in experimental AKI.
Several strategies have been adopted to achieve reprog-
ramming, namely, iPSC technology, SCNT, cell fusion,
and cell-extract treatment (Gurdon, 2006; Ha˚kelien et al.,
2002; Tada et al., 1997; Takahashi and Yamanaka, 2006).
Among these approaches, the use of cell extracts has
gained attention because it is an oocyte-independent re-
programmingmethod devoid of ethical and legal concerns
and does not pass through the pluripotent state, which is
an emerging desirable scientific goal.
Here,weusedhumanBMSCs,anattractivecellpopulation
for clinical application due to their accessibility, expansion
potential, genetic stability, and the presence of anunmethy-
lated genome, which render them prone to reprogramming
(Biancoetal., 2013; LeBlancandMougiakakos,2012;Morigi
and Benigni, 2013; Morigi et al., 2008; Streckfuss-Bo¨meke
et al., 2013). Our work provides evidence that human
BMSCs can be reprogrammed into a developmentally
distinct tubular lineage based on multifaceted approaches
spanning from cell morphology documented using trans-
mission and scanning electron microscopy to mRNA
sequencing revealing an abundance of tubular epithelial
transcripts and expression of proteins characteristic of renal
proximal tubular cells. The paradigm that BMSCs can be
driven toward a renal fate, also evidenced by the acquisition
of proximal tubular functional competence such as TER and
albumin binding and uptake activity, points the way to an
efficient methodology for generating renal cell types by
using a readily available autologous cell source.
In search of mechanisms responsible for BMSC reprog-
ramming, we attempted to uncover the actual blueprint
for reprogramming, which resides in the cell-free extract
of tubular epithelia, by depleting it of various putative
mediators of the process. Specifically, the requirement for
the combination of nuclear and cytoplasmic factors is dis-
closed. Moreover, reprogramming does not occur if depro-
teinated or RNA-depleted extracts are used.
The use of a kidney re-aggregation assay (Xinaris et al.,
2012), which represents a stringent ex vivo model for
the evaluation of the renal potential of a test population
(Hendry et al., 2013), contributes to further proving the
identity of the reprogrammed BMSCs. Reprogrammed cells
in the presence of embryonic kidney cells showed a remark-
able ability to form three-dimensional chimeric tubular
structures, indicating the efficient switch toward a renal
cell phenotype. Importantly, the reprogramming of BMSCs
toward a renal lineage reported herein may have clinical
applications in the future. Cell treatment with reprog-
rammed BMSCs partly improved renal function and sig-
nificantly limited tubular injury in mice with AKI. This
beneficial effect is ascribed to the high engraftment and694 Stem Cell Reports j Vol. 4 j 685–698 j April 14, 2015 j ª2015 The Authointegration of infused cells into damaged proximal tubuli
of AKImice. Such integration does not occur when animals
with AKI are infused with BMSCs, which preferentially
localize at the peritubular space (Humphreys and Bon-
ventre, 2008; Morigi and Benigni, 2013; Morigi et al.,
2008), highlighting the different nature of reprogrammed
versus native BMSCs. Another peculiar feature of reprog-
rammed BMSCs was their localization in different organs
after systemic infusion. In nonobese diabetic severe com-
bined immunodeficiency mice with AKI, reprogrammed
BMSCs were detected and/or entrapped predominantly in
lung and, to a very low extent, in the spleen and the liver,
while native BMSCs were found in limited numbers in
these organs (Franc¸ois et al., 2006; To¨gel et al., 2005). A cor-
ollary of the present results are previous reports demon-
strating improved survival and augmented kidney function
in rodent models of kidney disease after injection with a
mixed renal tubular cell population (Kelley et al., 2010).
Extract-induced reprogramming, by virtue of the high
yield, permits the derivation of a large number of isogenic
renal cell clones. Moreover, these cells can be stored and
retrieved upon request without losing their identity.
Thus, the reprogrammed BMSCs can be a tool for drug
screening and toxicological assays.
In summary, reprogramming BMSCs with the cell-free
extracts of epithelial or other fully differentiated somatic
cells, when successful, brings to the fore the flexibility
and choice of designer engineering. This approach and its
future refinements could potentially fulfill the quest to
utilize somatic cell types in a precursor state for durable
cell therapy.EXPERIMENTAL PROCEDURES
Cell Culture
The human immortalized proximal tubular cell line HK2 (CRL-
2190, ATCC) was cultured in keratinocyte serum-free medium
(Clonetics, Life Technologies) supplemented with bovine pituitary
extract and epidermal growth factor. Experiments were performed
at passages 20–40. Human BMSCs from two different donors were
obtained from the Transplantation Program of the Haematology
Division of Azienda Ospedaliera Papa Giovanni XXIII, Bergamo,
Italy. Cells were cultured as previously described (Capelli et al.,
2007) using low-glucose DMEM (Sigma-Aldrich) supplemented
with 5% human platelet lysate. Experiments were performed at
passages 4–6.
Cell Extracts
HK2 cell extracts were prepared as previously described (Ha˚kelien
et al., 2002). In brief, 100 3 106 cells were washed twice in
ice-cold PBS and once in cold cell lysis buffer (10 mM HEPES
[pH 8.2], 50 mM NaCl, 5 mMMgCl2, 1 mM DTT, and 1:100 prote-
ase inhibitors; all from Sigma-Aldrich) sedimented at 300 3 g for
10 min at 4C. The volume of cell pellet was added with an equalrs
volume of cold lysis buffer and incubated for 45 min on ice. Cells
were sonicated on ice in 200-ml aliquots using a sonicator fitted
with a 2-mm diameter probe (60% output; Heat Systems) until
all cells and nuclei were lysed, as judged by microscopy. The lysate
was sedimented at 15,000 3 g for 15 min at 4C. The supernatant
was aliquoted in 100-ml aliquots and used immediately for reprog-
ramming assays of 100,000 BMSCs.
SLO Permeabilization and Cell-Extract Treatment
Preliminary experiments were performed in order to define
the optimal concentration of SLO (Sigma-Aldrich) for BMSCs
using concentrations of 100, 200, 300, 400, 500, 600, 700, and
800 ng/ml. Permeabilization efficiency of >80% was obtained at
400 ng/ml, as assessed by monitoring the uptake of an Mr 70,000
Texas-red-conjugateddextran (50mg/ml;Molecular Probes, Invitro-
gen). Cell viability, assessed by trypan blue exclusion assay, was not
affected by the chosen SLO concentration. BMSCs were washed
twice in cold PBS and once in ice cold Ca2+- and Mg2+-free Hank’s
balanced salt solution (HBSS; Gibco, Invitrogen). Cells were resus-
pended in aliquots of 100,000 cells in HBSS in 1.5-ml tubes and
centrifuged at 1,500 rpm for 5 min at 4C. Cells were suspended
in ice-cold HBSS containing 400 ng/ml SLO and incubated for
50 min at 37C and finally centrifuged at 1,500 rpm for 5 min at
4C. Permeabilized BMSCs were exposed to HK2 cell extract con-
taining an ATP-regenerating system (1mmol/l ATP, 10mmol/l cre-
atinephosphate,25mg/ml creatine kinase; 100mmol/lGTP; all from
Sigma-Aldrich) and 1 mmol/l of each nucleotide triphosphate
(Roche Diagnostics) and incubated for 1 hr at 37C. So that BMSC
membranes could be resealed, the cell suspension was diluted with
HK2 cell medium containing 2 mM CaCl2, and cells were seeded
in a six-well plate. As a control, permeabilized BMSCs were grown
in HK2 cell medium. Where needed, HK2 cell extracts were incu-
bated as follows: (1) at 100C for 5min or (2) with 100 mg/ml RNase
A (Roche diagnostics) for 30 min, followed by 1 hr incubation with
RNase inhibitor (1 mg/ml; Ambion, Invitrogen). In some experi-
ments, HK2 cells were treated with 25 nM trichostatin A or 50 nM
5-aza-cytidine (both from Sigma-Aldrich) or both 48 hr before pre-
paring the extract (Rajasingh et al., 2011). The reprogramming ex-
perimentswere repeated successfully 15outof 17 timeswithhuman
BMSCs from two different donors, generating epithelial cells at the
same timing as observed with light microscopy (i.e., 13–15 days).
CDH1 EGFP Transfection
CDH1 EGFP plasmid was obtained commercially (Genecopeia;
HPRM12692-PF02). Human BMSCs, BMSCs treated with HK2 cell
extracts (at days 5 and 11 post reprogramming assay), and HK2
cells grown on six-well plates were transfected with 2.5 mg of
plasmid using lipofectamine 2000 (Invitrogen, Life Technologies)
according to the manufacturer’s instructions. Representative im-
ages were taken 24 hr post-transfection (days 6 and 12) using an
Apotome microscope (Axion Vision, Imager 2Z, Zeiss).
RNA Sequencing
Two biological replicates were performed for each cell lineage.
Poly(A)+ RNA was obtained from 20 mg of total RNA using the
Dynabeads mRNA DIRECT Micro Kit after adding external RNA
spike-in controls (External RNA Controls Consortium). LibrariesStemwere prepared using the Ion Total RNA-Seq Kit v2. Template prep-
aration and sequencing were performed using the Ion PGM Tem-
plate OT2 200 Kit and the Ion PGM Sequencing 200 Kit v2. Each
replicate was sequenced on the Ion PGM Sequencer using an Ion
318 Chip. Data extraction, base calling, and alignment were per-
formed using TorrentSuite Software 3.6. To count reads overlap-
ping with known exon coordinates (RefSeq, UCSC Genome
Browser), we used the HTSeq software through a modified version
of the FeatureCounter plugin that allowed it to discard reads with
mapping quality score < 5. Differential expression analyses were
performed on genes showing five or more reads in both replicates
in at least one cell lineage using edgeR and RobiNA software. Func-
tional pathway analysis was performed with the GraphiteWeb and
the ToppFun softwares using a two-step strategy. First, we analyzed
genes showing the most striking changes, defined as p % 0.05
(with Benjamini-Hochberg multiple testing correction),R10-fold
change, and expression levels of three or more reads per kilobase
per million in at least one cell lineage. Second, we analyzed all
genes with p-corrected% 0.05 andR 2-fold change.
TER Measurement
Human BMSCs and CL17 and HK2 cells were plated in 24-well
transwell filters of 0.2 mm pore size (Corning) at a concentration
of 250,000/0.5 ml in triplicate. Cells were used for TER measure-
ment (Millicell ERS; Millipore) 48 hours after reaching confluency.
TER (Ohm/cm2) was measured at 37C, and measurements were
performed twice every 10 min according to the manufacturer’s
instructions.
In Vivo Experiments
Female 2-month-old NOD.CB17-Prkdc scid/NcrCrl (NOD-SCID)
mice (Charles River Italia) were used. Animal care and treatment
were conducted in conformity with institutional guidelines and
international laws and policies (Morigi et al., 2011). Animal studies
were approved by the institutional animal care and use committees
of Mario Negri Institute, Milan, Italy.
AKI was set up in NOD-SCID mice by subcutaneous injection of
the nephrotoxic drug cisplatin (Ebewe Italia) at a dose of 13 mg/kg
as previously described (Morigi et al., 2008). For investigation of
the effect of reprogrammed cells (CL17), 24 hr after cisplatin injec-
tion, mice received intravenous (tail vein) saline (n = 5) or CL17
cells at passage 16 (n = 6). Mice were injected with 5 3 105 cells
(50% of cells were labeled with PKH26, Sigma-Aldrich). This exper-
iment was performed once. The animals were euthanized 4 days
after cisplatin injection, and kidney, lung, heart, spleen, and liver
were used for histology and immunohistochemistry evaluation.
Cell engraftment was evaluated in paraformaldehyde-lysine-peri-
odate-fixed cryosections.
Renal function was assessed using blood urea nitrogen (BUN)
levels measured by the Reflotron test (Roche Diagnostics). Basal
BUN levels of NOD-SCID mice averaged 22 ± 2 mg/dl. BUN levels
exceeding this range of values were considered abnormal.
Statistical Analysis
Results are expressed as mean ± SD. Data were analyzed using
the t test for unpaired data. Statistical significance was defined as
p < 0.05.Cell Reports j Vol. 4 j 685–698 j April 14, 2015 j ª2015 The Authors 695
See the Supplemental Experimental Procedures for details
regarding the generation of clones using limiting dilution and
duplication time measurement, transmission electron microscopy
and scanning electron microscopy, immunocytochemistry and
flow cytometry, renal histology and immunohistochemistry anal-
ysis, RNA extraction and qRT-PCR, albumin binding and uptake
assays, and renal organoids.
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